Neurocrine Biosciences’ (NBIX) “Buy” Rating Reaffirmed at Canaccord Genuity Group
Canaccord Genuity Group reissued their buy rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report published on Thursday, Benzinga reports. Canaccord Genuity Group currently has a $150.00 price target on the stock. NBIX has been the topic of several other reports. Cantor Fitzgerald reissued an overweight rating on shares of Neurocrine […]
More Stories
Brunswick Bancorp (OTCMKTS:BRBW) and Republic Bancorp (NASDAQ:RBCAA) Head to Head Comparison
Republic Bancorp (NASDAQ:RBCAA – Get Free Report) and Brunswick Bancorp (OTCMKTS:BRBW – Get Free Report) are both small-cap finance companies,...
Great Valley Advisor Group Inc. Has $20.77 Million Holdings in Visa Inc. (NYSE:V)
Great Valley Advisor Group Inc. raised its stake in Visa Inc. (NYSE:V – Free Report) by 3.3% during the 3rd...
Camden National Bank Cuts Stock Holdings in The Home Depot, Inc. (NYSE:HD)
Camden National Bank trimmed its position in shares of The Home Depot, Inc. (NYSE:HD – Free Report) by 0.4% in...
Sysco Co. (NYSE:SYY) Shares Purchased by Leelyn Smith LLC
Leelyn Smith LLC boosted its stake in Sysco Co. (NYSE:SYY – Free Report) by 5.0% in the 3rd quarter, according...
Stonebrook Private Inc. Lowers Position in Johnson & Johnson (NYSE:JNJ)
Stonebrook Private Inc. trimmed its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.5% during the 3rd quarter,...
49 Wealth Management LLC Grows Stock Position in Pfizer Inc. (NYSE:PFE)
49 Wealth Management LLC increased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 7.4% in the 3rd quarter,...